GeoVax Labs, Inc. (GOVX) Financial Statements (2026 and earlier)

Company Profile

Business Address 1900 LAKE PARK DRIVE
SMYRNA, GA 30080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,5076,45327,61311,4249,884283
Cash and cash equivalent5,5076,45327,61311,4249,884283
Receivables 659     
Prepaid expense244150155   
Other undisclosed current assets1,5251,2831,171205351164
Total current assets:7,9357,88628,93911,62910,235447
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization15021023515714811
Other noncurrent assets711,1882,174   
Other undisclosed noncurrent assets    111111
Total noncurrent assets:2211,3972,40916815922
TOTAL ASSETS:8,1569,28331,34811,79710,394469
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,1073,5204,7485,4356272,004
Accounts payable1,8502,8031,7482,058268153
Accrued liabilities1,2587173,0003,3783591,851
Debt     18313
Total current liabilities:3,1073,5204,7485,4358102,016
Noncurrent Liabilities
Long-term debt and lease obligation     1527
Long-term debt, excluding current maturities     1527
Other undisclosed noncurrent liabilities    2,000  
Total noncurrent liabilities:    2,0001527
Total liabilities:3,1073,5204,7487,4358252,043
Equity
Equity, attributable to parent5,0495,76326,6004,3629,569(1,575)
Preferred stock     761,932
Common stock11226640
Additional paid in capital134,394110,125104,97168,73155,29539,340
Accumulated deficit(129,356)(104,364)(78,397)(64,376)(45,806)(42,848)
Total equity:5,0495,76326,6004,3629,569(1,575)
TOTAL LIABILITIES AND EQUITY:8,1569,28331,34811,79710,394469

Income Statement (P&L) ($ in thousands)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues3,955 823861,8241,176
Gross profit:3,955 823861,8241,176
Operating expenses(29,099)(26,743)(14,110)(19,131)(4,640)(3,548)
Operating loss:(25,144)(26,743)(14,029)(18,746)(2,817)(2,372)
Nonoperating income (expense)1527767176(141)2
Investment income, nonoperating1737767526
Interest and debt expense (21)  172(144)(4)
Loss from continuing operations:(25,014)(25,967)(14,021)(18,398)(3,102)(2,375)
Loss before gain (loss) on sale of properties:(18,398)(3,102)(2,375)
Net loss:(25,014)(25,967)(14,021)(18,398)(3,102)(2,375)
Other undisclosed net income (loss) attributable to parent 21  (172)1444
Net loss available to common stockholders, diluted:(24,992)(25,967)(14,021)(18,570)(2,958)(2,371)

Comprehensive Income ($ in thousands)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(25,014)(25,967)(14,021)(18,398)(3,102)(2,375)
Comprehensive loss, net of tax, attributable to parent:(25,014)(25,967)(14,021)(18,398)(3,102)(2,375)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: